Evaluation of FeNO During and Following Acute COPD Exacerbation

The purpose of this research study is to determine whether exhaled nitric oxide (FeNO) goes
up during an acute exacerbation of COPD and whether the level of exhaled nitric oxide returns
to normal in the weeks after an exacerbation. FeNO is measured with a medical device called
the NIOX MINO®. The NIOX MINO® device has been cleared by the Food and Drug Administration
(FDA) for use in children and adults age 7 and older to measure Fractional Exhaled Nitric
Oxide (FeNO) in human breath.This information will be useful for determining whether FeNO may
help predict the development of a COPD exacerbation and/or be useful for identifying patients
who will have a beneficial therapeutic response to inhaled or systemic corticosteroids during
a COPD exacerbation.

Inclusion Criteria:

- Age: 40 years and above, inclusive

- Sex: Males and Females

- Smoking History: ≥20 pack years.

- COPD Defined as an FEV1/ FVC or FEV1/SVC ratio <70% predicted.

- AECOPD defined as a clinically significant worsening of COPD symptoms requiring
treatment with antibiotics and/or systemic steroids and/or hospitalization for same.

Exclusion Criteria:

- Use of Systemic Corticosteroids for more than 48 hours prior to Visit 1.

- AECOPD requiring mechanical ventilation

- Study Participation Outside of This Protocol: Patients currently enrolled in studies
of Investigational or non-Investigational Drugs or Medical Devices and/or who
participated in these studies within 30 days prior to this study are excluded.